Lu AF35700
Sponsors
H. Lundbeck A/S
Conditions
Cytochrome P450 InteractionDrug ReactionsHealthyHepatic ImpairmentRenal FailureSchizophreniaTreatment-resistant Schizophrenia
Phase 1
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
CompletedNCT02202226
Start: 2013-01-31Updated: 2015-03-06
Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700
CompletedNCT02333487
Start: 2014-12-30End: 2016-02-11Updated: 2020-05-12
Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women
CompletedNCT03103646
Start: 2017-03-28End: 2019-07-19Updated: 2019-10-02
Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects
CompletedNCT03189615
Start: 2017-05-14End: 2018-04-23Updated: 2018-05-04
Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes
CompletedNCT03195946
Start: 2017-06-16End: 2018-01-03Updated: 2018-01-08
Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment
TerminatedNCT03241147
Start: 2017-07-25End: 2019-07-24Updated: 2019-09-30
Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State
CompletedNCT03670082
Start: 2018-09-05End: 2019-01-13Updated: 2019-11-01
Phase 3
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
CompletedNCT02717195
Start: 2016-04-30End: 2018-10-08Updated: 2019-11-25
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
CompletedNCT02892422
Start: 2016-08-31End: 2019-10-10Updated: 2020-10-26
Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
TerminatedNCT03230864
Start: 2017-07-20End: 2019-02-05Updated: 2020-01-21